Circadian-Phase Anchored Low-Dose Melatonin for Prevention
🧪 Overview
Evening administration of 0.5-1mg melatonin 2-3 hours before dim light melatonin onset maximizes circadian entrainment and reduces AD risk through glymphatic clearance enhancement. However, critical PK issues emerge: 0.5-1mg oral melatonin produces peak serum levels of 500-4000 pg/mL (not 50-200 pg/mL as claimed), fundamentally disconnecting the physiological replacement premise. Glymphatic mechanism is not melatonin-specific. DLMO targeting is operationally impossible outside research settings. The hypothesis requires fundamental redesign: if PK issue is acknowledged and DLMO replaced with practical evening timing, this collapses toward H7 with added circadian claims.
🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["MT1/MT2<br/>Melatonin Receptors"]
B["CLOCK/BMAL1<br/>Circadian Clock"]
C["Melatonin<br/>Phase-Anchored Low-Dose"]
D["Sleep<br/>Restoration"]
E["Neuroprotective<br/>Signaling"]
F["Beta-Amyloid<br/>Clearance"]
G["Tau<br/>Phosphorylation Reduction"]
H["Cognitive<br/>Preservation"]
A --> B
B --> C
C --> D
D --> E
E --> F
E --> G
F --> H
G --> H
style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — MT1
No curated PDB or AlphaFold mapping for MT1 yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for MT1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF middle-aged adults (45-65) with circadian rhythm disturbances receive 0.3mg oral melatonin (adjusted for corrected PK profile) at a fixed practical clock time (20:00-21:00) rather than an untimed c | Sleep efficiency improvement from baseline ≥5% and WASO reduction ≥15 min in the fixed-timing melatonin group vs. no-treatment control, with polysomnographic me | — no observation — | pending | 0.55 |
| IF older adults (≥60 years) with normal cognition receive 0.3mg oral melatonin at a fixed clock time 3 hours before habitual sleep onset (rather than 0.5-1mg at claimed DLMO timing), THEN overnight CS | No significant difference in overnight CSF Aβ42 concentration change from baseline between 0.3mg melatonin timed 3h before sleep onset and placebo (difference < | — no observation — | pending | 0.45 |
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |